1. Generics Bulletin
  2. >>Products
  3. >>Generics

Indivior Sets Out Next Steps As It Braces For Suboxone Rivals

 
• By Dave Wallace

Indivior is exhausting all its options to try and stop the impending launch of US generic rivals to Suboxone from 19 February, including petitioning the country’s Supreme Court to intervene. But even if Dr Reddy’s and Alvogen do launch their versions next week, the originator is planning to combat them with an authorized generic.

HurricaneBeach
Indivior Is Bracing Itself For Generic Competition To Hit Suboxone • Source: Shutterstock

Indivior is bracing itself for an “expected material and rapid loss of Suboxone (buprenorphine/naloxone) film net revenue in the US” following the imminent launch of generic versions, after an appeals court denied emergency motions filed by the originator to delay a mandate that will allow Alvogen and Dr Reddy’s to launch their versions ‘at risk’ from Tuesday 19 February.

“In response, Indivior will file a petition with the Supreme Court of the US,” the originator said. It is asking the Supreme Court to stay the mandate, pending a certiorari petition that is attempting to overturn the appeals court’s decision in November last year to vacate a preliminary injunction granted against Dr Reddy’s

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

US FDA Expands Surprise Foreign Inspections

 
• By Sue Sutter

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

More from Products

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.

Apotex Extends Formosa Ophthalmic Alliance Into Mexico

 
• By Dave Wallace

Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.

Fresenius Kabi Lauds Tocilizumab Momentum As ‘Intense’ Transfer To mAbxience Continues

 
• By Dean Rudge

Fresenius Kabi continued to reap the rewards of its fledgling commercial Biopharma business in the first quarter, as the firm eyes further growth for its tocilizumab biosimilar in the US and Europe in the second half of 2025.